drugset / Trial / NCT06552858
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study aims to investigate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib for platinum-resistant recurrent ovarian cancer through a single-center, prospective, single-arm, phase II clinical trial, to improve the overall treatment level and prognosis of platinum-resistant ovarian cancer.
Timeline
- Start
- 2024-09-01
- Primary completion
- 2026-09-01
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalpiciclib | Small molecule | 150 mg | Oral |
| Subject | Fluzoparib | Small molecule | 150 mg | Oral |